Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor

Abstract

A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulae a tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein.

1 - 9 . (canceled) 
     
     
         10 . A method of treating cancer in a subject, comprising administering to the subject an effective amount of a compound, which is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole, 5-hydroxy-4-(5-hydroxy-4-(1-methyl-1H-indol-5-yl)-4H-1,2,4-triazol-3-yl)-2-isopropylphenyl dihydrogen phosphate, or a tautomer, or a pharmaceutically acceptable salt thereof, and an effective amount of an EGFR inhibitor. 
     
     
         11 - 12 . (canceled) 
     
     
         13 . The method of  claim 10 , wherein the cancer is pancreatic cancer, ovarian cancer, gastrointestinal cancer, prostate cancer, rectal cancer, kidney cancer, liver cancer, gallbladder cancer, head and neck cancer, transitional cell carcinoma, squamous cell carcinoma, melanoma, glioblastoma, gliosarcoma, colorectal cancer, breast cancer, esophageal cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, brain and central nervous system cancer, neuroendocrine tumors, lymphoma, multiple myeloma, or chronic lymphocytic leukemia. 
     
     
         14 . The method of  claim 13 , wherein the cancer is pancreatic cancer. 
     
     
         15 - 19 . (canceled) 
     
     
         20 . The method of  claim 10 , wherein the subject is human. 
     
     
         21 - 26 . (canceled) 
     
     
         27 . The method of  claim 10 , wherein the compound is 3-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(1-methyl-indol-5-yl)-5-hydroxy-[1,2,4]triazole, or a tautomer or a pharmaceutically acceptable salt thereof. 
     
     
         28 . The method of  claim 10 , wherein the EGFR inhibitor is gefitinib or cetuximab. 
     
     
         29 . The method of  claim 10 , wherein the cancer is pancreatic cancer and the EGFR inhibitor is gefitinib or cetuximab.